Strong 2026 IPO activity, with 127 U.S. deals priced year-to-date through mid-October and global proceeds already exceeding prior records in several markets, reflects robust risk appetite and equity valuations supporting new listings. Biotech and smaller offerings continue to price weekly, while mega-cap candidates face selective conditions amid high valuations, elevated Treasury yields, and AI spending scrutiny that have prompted delays or postponements. Anthropic targets a potential October or Q4 Nasdaq debut near $2 trillion, and Jio Platforms is slated for late October in India, but several high-profile names including OpenAI have signaled timelines shifting into 2027. Trader sentiment on near-term resolutions hinges on execution of these announced deals before year-end amid volatile equity markets and seasonal factors.